Active, not recruitingPHASE1, PHASE2NCT05468697
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Belzutifan(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (13)
- Georgetown University Medical Center ( Site 1002), Washington D.C., District of Columbia, United States
- University of Chicago Medical Center ( Site 1007), Chicago, Illinois, United States
- Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 1001), Boston, Massachusetts, United States
- Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 1004), Salt Lake City, Utah, United States
- Macquarie University-MQ Health Clinical Trials Unit ( Site 2001), Macquarie University, New South Wales, Australia
- Westmead Hospital ( Site 2006), Westmead, New South Wales, Australia
- Frankston Hospital-Oncology and Haematology ( Site 2005), Frankston, Victoria, Australia
- One Clinical Research ( Site 2008), Nedlands, Western Australia, Australia
- Emek Medical Center-oncology ( Site 3003), Afula, Israel
- Rambam Health Care Campus-Oncology ( Site 3000), Haifa, Israel
- Shaare Zedek Medical Center-Oncology ( Site 3002), Jerusalem, Israel
- Rabin Medical Center-Oncology ( Site 3004), Petah Tikva, Israel
- Sourasky Medical Center ( Site 3005), Tel Aviv, Israel
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05468697 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
See all trials for Acquired cystic disease-associated renal cell carcinoma →